Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data
Filing Expected Before Year-End
Executive Summary
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
You may also be interested in...
One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly
AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.
Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.